February 6, 2025
The Rivalry Continues
Having covered the wacky world for more than 30 years there are certain constants we can count on. When Diabetic Investor began publishing Novo Nordisk and Lilly were battling it out in the insulin market. Way back then Lilly was the leader Novo was the upstart but coming on strong. Thanks to a series of missteps by Lilly Novo became the leader forcing Lilly to reexamine how they did business.
Today these two longtime rivals are battling it out in the GLP1 market, with insulin now an afterthought for both companies. Here it was Lilly who fell behind early but . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
